Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective

Abstract Background A head-to-head study demonstrated the superiority of once-daily umeclidinium bromide/vilanterol (UMEC/VI) 62.5/25 mcg on trough forced expiratory volume in 1 s (FEV1) versus once-daily tiotropium/olodaterol (TIO/OLO) 5/5 mcg in symptomatic patients with chronic obstructive pulmon...

Full description

Bibliographic Details
Main Authors: M. T. Driessen, J. Whalen, B. Seewoodharry Buguth, L. A. Vallejo-Aparicio, I. P. Naya, Y. Asukai, B. Alcázar-Navarrete, M. Miravitlles, F. García-Río, N. A. Risebrough
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Respiratory Research
Subjects:
Bronchodilators
Chronic obstructive pulmonary disease
Cost effectiveness
Economic evaluation
Health resources
LAMA/LABA
Online Access:http://link.springer.com/article/10.1186/s12931-018-0916-7

Internet

http://link.springer.com/article/10.1186/s12931-018-0916-7

Similar Items